Glossary
:
Legal/Privacy
:
Contact
Product Pipeline :
Influenza
HIV
Hepatitis C
Influenza
Vaccine Market
Hepatitis B
Rotavirus
Mosquito diseases
Breast Cancer
Influenza
PepTcell has applied its breakthrough technology to the development of Flu-v, a new class of T cell vaccines that are effective against the highly mutagenic influenza virus. Flu-v is the Company’s lead product that has been developed to provide a single treatment flu vaccine which is effective against all strains of flu virus, including pandemic strains.
Using a novel proprietary
epitope
prediction algorithm, PepTcell has successfully identified regions of flu virus that have not changed over 60 years, in both human and animal strains of the virus. This allows Flu-v to target conserved regions of the virus conferring long-term protection against the threat of emerging strains.
Current flu vaccines only work against specific virus strains. As these strains mutate frequently, vaccines also need to be updated. As such they do not provide protection against emerging pandemic flu strains, such as seasonal or avian flu.
Unlike traditional vaccines which are grown in highly specialised facilities and whose production is limited by egg supply and the process of growing a vaccine, Flu-v can be quickly and easily manufactured in chemical plants. This allows the vaccine to be made and administered in large quantities prior to a pandemic outbreak, enabling a large proportion of the world to be protected.
The majority of pre-clinical proof of principle studies have been completed and the vaccine will soon begin clinical trials in the UK.
Find more information on Flu-v in the animation and report.
Related Links
Flu-V Whitepaper
Read more...